Corcept Therapeutics Inc. Stock
Corcept Therapeutics Inc. gained 1.680% today.
Corcept Therapeutics Inc. is currently one of the favorites of our community with 13 Buy predictions and no Sell predictions.
Based on the current price of 29.55 € the target price of 122 € shows a potential of 312.86% for Corcept Therapeutics Inc. which would more than double the current price.
For the coming years our community has positive and negative things to say abot the Corcept Therapeutics Inc. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Worthwhile Investment for the next years" there were negative voices in the community.
Pros and Cons of Corcept Therapeutics Inc. in the next few years
Pros
?
C******** o* t** e**********
?
M***** P*******
?
S********** s********
Cons
?
G***** c******* t* c**********
?
B****
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Corcept Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Corcept Therapeutics Inc. | 1.680% | -12.132% | -1.860% | -52.308% | -56.786% | 41.252% | 33.108% |
| Rockwell Medical Inc. | -1.740% | 0.059% | -19.516% | -50.641% | 25.277% | -63.152% | -94.250% |
| Pacira Pharmaceuticals | -4.570% | 2.732% | 13.939% | -22.314% | -12.963% | -51.042% | -69.180% |
| Twist Bioscience Corp | -5.360% | -0.218% | 15.921% | -4.029% | 47.971% | 95.077% | -67.032% |
Comments
Corcept Therapeutics (NASDAQ:CORT) had its price target lowered by analysts at HC Wainwright from $105.00 to $67.00. They now have a "buy" rating on the stock.
Show more
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics (NASDAQ:CORT) was given a new $105.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock.
Show more
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics (NASDAQ:CORT) had its price target lowered by analysts at HC Wainwright from $145.00 to $90.00. They now have a "buy" rating on the stock.
Show more
Ratings data for CORT provided by MarketBeat
News
Corcept Insider Transaction Explained After Shares Tumble 50% in One Day
On Tuesday, William Guyer, the chief development officer of Corcept Therapeutics (NASDAQ:CORT), exercised and immediately sold 20,000 shares through open-market transactions totaling approximately
